Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
29 May, 2017 11:24 IST
Aurobindo Pharma gets USFDA nod for anti-cough tablets
Source: IRIS | 21 Mar, 2017, 09.14AM
Comments  |  Post Comment

Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg (OTC). Aurobindo's Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets are the AB rated generic equivalent of Reckitt Benckiser's Mucinex DM tablets. The product will be launched in Q1FY18.

Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets helps loosen mucus and phlegm, and thin out bronchial secretions, making coughs more productive. The approved product has an estimated market size of US$ 235 million for the twelve months ending December 2016 according to IRI database.

This is the 106 th ANDA (including 21 tentative approvals) approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 311 ANDA approvals (272 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Shares of the company gained Rs 1.7, or 0.24%, to trade at Rs 704.90. The total volume of shares traded was 0 at the BSE (9.01 a.m., Tuesday).



Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Reliance Comm swings to loss in Jan-Mar quarter - 29-May-2017 11:01
Tech Mahindra quarterly net drops 33% - 29-May-2017 10:51
Bank of Baroda to raise Rs 90 bn through equity dilution - 29-May-2017 09:58
JSPL completes 6 MTPA integrated steel plant at Angul - 29-May-2017 09:46
Zydus Cadila gets final approval for Acamprosate Calcium Tablets - 29-May-2017 09:41
Glenmark receives final approval for generic version of Bystolic Tablets - 29-May-2017 09:22
Strides Shasun completes USFDA inspection at Bangalore facility with 3 observations - 29-May-2017 09:18
Ashok Leyland turns to profit in Jan-Mar quarter - 26-May-2017 17:40
ITC Q4 profit climbs 12% to Rs 26.69 bn - 26-May-2017 16:50
Maruti Suzuki to start 15 automobile skill enhancement centres - 26-May-2017 11:08
Tata Power Renewable Energy raises Rs 5 bn via NCDs - 26-May-2017 11:00
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer